Top 50 Ai For Computational Biology in Europe

Boltz provides an AI‑driven platform that accelerates drug discovery by enabling rapid, large‑scale virtual screening of small molecules and protein designs, delivering near‑FEP affinity predictions up to 1,000× faster than traditional methods. Its modular agents—Boltz‑1 for all‑atom co‑folding, Boltz‑2 for ultra‑fast affinity prediction, and BoltzGen for universal binder design—integrate experimental feedback to continuously improve model accuracy for pharmaceutical, biotech, and academic research.

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

This startup uses AI to analyze previously unexamined regions of the human genome, translating complex genetic data into actionable insights. Their technology helps healthcare providers enhance patient care and accelerates drug discovery by revealing new genetic associations.

The startup specializes in protein engineering using machine learning techniques to accelerate drug development processes. By optimizing protein design, the company aims to enhance the efficacy and reduce the time required for new therapeutic solutions.

Helical AI provides a Virtual AI Lab platform that bridges the gap between machine learning models and biological decision-making in R&D. The platform offers biologists self-serve tools for designing and evaluating in-silico experiments, while ML engineers gain a production environment for model personalization and alignment. This integrated approach accelerates discovery in areas like target identification and therapeutic design, leading to higher hit rates for pharmaceutical research teams.

Kuano provides quantum simulation and artificial intelligence solutions specifically tailored for drug design applications. The company leverages advanced computational methods to enhance the discovery process for new therapeutics. This technology assists pharmaceutical researchers in exploring molecular interactions with greater precision.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Passkey Therapeutics utilizes its Locksmith® platform, which employs AI-enhanced computational genetics, to identify synergistic pairs of biological pathways for therapeutic intervention. This technology enables the development of novel drug combinations and multifunctional drugs targeting complex diseases. The company focuses on creating a new class of synergistic therapies by moving beyond the single-target drug development paradigm.

Artificial Intelligence Expert utilizes machine learning algorithms to analyze biomedical data, enhancing research accuracy and efficiency. The company addresses the challenge of data interpretation in the biomedical field, enabling researchers to derive actionable insights from complex datasets.

Adaptyv Bio offers an automated cloud lab platform that conducts protein assays and delivers clean, labeled data for AI-driven protein design within three weeks. The service integrates ordering, experiment management, and data analysis through a comprehensive API, enabling seamless incorporation into existing workflows. Transparent per‑protein pricing and real‑time progress updates help teams accelerate lab‑in‑the‑loop protein engineering cycles.

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

Receptor.AI uses artificial intelligence to accelerate the drug discovery process. Their platform helps researchers identify and develop new drug candidates more efficiently.

Sortera Bio generates millions of sequence-function pairs per experiment using its Deep Screening platform. This data accelerates AI-driven biologics discovery by providing comprehensive datasets for identifying novel drug leads, even against challenging targets like membrane proteins.

InstaDeep develops AI-powered decision-making systems utilizing GPU-accelerated computing, deep learning, and reinforcement learning to tackle complex challenges in industries such as logistics, energy, and biology. Their technology enhances operational efficiency and precision, enabling enterprises to make data-driven decisions in an increasingly AI-centric landscape.

AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.

Nabla Bio utilizes biologically informed machine learning and experimental technologies to design antibodies with atomic precision, targeting complex disease mechanisms such as GPCRs and ion channels. The platform enhances drug manufacturability, safety, and efficacy by integrating AI-driven design with empirical measurement of human-relevant drug properties.

Dioclea Labs develops AI-powered sampling algorithms that improve the accuracy of predicting experimental results in drug discovery. Their technology enhances predictions of binding affinity and efficiency, accelerating the identification of promising drug candidates.

Syndex Bio is a biotechnology platform that integrates molecular technologies and artificial intelligence to enhance the diagnosis and treatment of diseases. By providing advanced tools for biological discovery, the company aims to improve healthcare outcomes through more accurate and efficient disease management.

Nuuron provides a platform for managing and analyzing complex data sets. The service focuses on delivering actionable insights through advanced computational tools. This allows users to streamline their data processing workflows efficiently.

Voredos SRL provides algorithmic solutions for analyzing large datasets in biology, biotechnology, and chemistry. Their technology enhances data processing efficiency, enabling researchers to derive actionable insights from complex biological and chemical data.

Elaniti develops a computational analog of soil by integrating generative AI with first-principles physics to simulate biogeochemical complexity. This platform enables dynamic functional inference, allowing users to predict soil performance and optimize on-farm management before implementing practices. By fusing molecular biology, environmental chemistry, and agronomic metadata, the company accelerates the transition to regenerative agriculture and enhances food security.

Aixa develops AI-driven biotech software that utilizes predictive genomics modeling to provide accessible health insights comparable to standard lab tests. By synthesizing advanced genomics data and medical literature, Aixa enables individuals to leverage personalized health solutions for improved healthspan.

Watershed provides a platform for biological data analysis that integrates secure data management, customizable workflows, and supercomputing resources to enable rapid, large-scale analyses across various omics disciplines. By offering a dedicated bioinformatics team and ready-to-use AI tools, Watershed enhances productivity and collaboration for researchers facing the challenges of complex data interpretation.

Baseimmune provides a computational protein‑engineering platform that designs custom antigen immunogens for chronic disease targets using AI‑enhanced epitope mapping and deep‑learning protein folding. The platform delivers rapid in‑silico design, high‑throughput expression, and integrated preclinical validation, offered as a licensable technology stack or managed service for pharmaceutical, biotechnology, and academic users.

DNA-LM develops a universal language model pre-trained on diverse DNA sequences to process entire genomes. This model aims to accurately predict phenotypic traits across molecular and organism scales, reducing the need for extensive labeled data.

The startup develops a drug discovery platform that combines artificial intelligence and synthetic biology to digitize natural diversity and identify potential drug candidates based on their functions. This approach aims to make the discovery of new therapeutics for cancer, metabolic diseases, and infectious diseases more predictable and cost-effective.

Mosaic Therapeutics develops targeted drug combinations for cancer treatment by utilizing genome-scale CRISPR screening and advanced computational models to identify effective therapies based on the molecular characteristics of tumors. The company addresses the challenge of cancer's complexity and heterogeneity, aiming to improve patient outcomes through precision medicine in biomarker-defined settings.

Aneira applies computational biology and machine learning to provide health and care services for women and families. The company leverages advanced data analysis to offer personalized health insights and support.

Seed Health leverages computational biology and ultra-deep sequencing to analyze host-microbe interactions, enabling the development of prebiotics, probiotics, and synbiotics that enhance gut health and overall well-being. The company addresses the lack of effective probiotic solutions by commercializing scientifically validated products that optimize the human microbiome across various life stages.

Multiomic Health develops precision medicines for diseases derived from metabolic syndrome by integrating multi-omics data with longitudinal clinical phenotyping. The company uses AI-enabled data science to identify distinct molecular disease drivers within patient subpopulations. This approach enables the origination of therapeutic R&D programs with corresponding patient-stratifying companion diagnostics for higher clinical trial success rates.

The startup develops analytics software that integrates multi-omic data with AI analytics to enhance drug candidate identification and biomarker discovery. This technology enables precision medicine organizations to streamline research processes and significantly reduce time-to-market for new treatments.

BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.

The startup develops a computational chemistry platform that utilizes data-driven algorithms and quantum chemistry to predict thermodynamic properties of biochemicals, such as solubility and phase equilibria. This technology provides scientists with a robust computing infrastructure for molecular dynamics simulations, facilitating the acceleration of experimental research.

Genenet Technology develops proprietary gene circuit designs by integrating deep learning algorithms to mimic artificial neural networks. This novel biocomputing method enables advanced control over gene expression for applications in synthetic biology and bioproduction. The company provides genetic circuit design services, R&D consultation, and technology licensing for drug discovery, cell and gene therapy, and organoid-on-chip research.

CoSyne Therapeutics applies polymathic Artificial Intelligence to accelerate precision medicine drug discovery, focusing specifically on underserved brain diseases. The company utilizes advanced computational methods to identify novel therapeutic targets and develop treatments for complex neurological conditions. This approach aims to significantly advance the pipeline for brain cancer and other challenging brain disorders.

Ensocell is a biotechnology company developing next-generation precision biologics for autoimmune and fibrotic diseases. The company utilizes the ENSO AI platform to identify molecular targets and predict disease biology with high precision. This approach informs the design of tailored therapeutics with improved clinical success potential.

The startup develops a medical analysis platform that integrates artificial intelligence with computational pathology to enhance diagnostic accuracy in cancer detection. By facilitating real-time collaboration between pathologists and AI, the platform improves decision-making in clinical diagnostics and drug development, ultimately increasing survival rates for cancer patients.

Deepflare provides an AI platform that predicts T-cell immunogenicity beyond simple binding affinity for antigen design. This platform accelerates discovery and de-risks drug pipelines by delivering superior candidate predictions with high accuracy. Users can design, iterate, and receive optimized candidates within 24 hours using integrated computational biology tools.

Exazyme is an AI-driven protein design tool that utilizes advanced algorithms to predict protein evolutions, enabling biotech companies to achieve superior outcomes with up to 100 times fewer experiments than traditional screening methods. The platform addresses the inefficiencies in protein optimization by allowing users to evaluate multiple protein properties simultaneously while ensuring data security through on-site deployment or API connections.

Imperagen has developed a fully automated platform that integrates AI-driven hotspot identification, precision DNA editing, and laboratory automation to enhance enzyme engineering. This technology significantly reduces the time and resources required for enzyme development, enabling rapid creation and optimization of enzyme variants across diverse applications.

Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.

SyntheticGestalt develops machine learning models specifically designed for drug discovery, enabling researchers to identify potential drug candidates more efficiently. Their software automates various research processes, reducing time and costs associated with traditional drug development methods.

Syngens AS has developed an AI-powered DNA Design Platform that enables precise and predictable DNA engineering for biomanufacturing applications. By optimizing gene expression and constructing novel biological pathways, the platform addresses the limitations of scalability and engineering precision in current biological methods, significantly reducing trial-and-error in experimental processes.

Econic Biosciences is developing a healthcare platform that targets extrachromosomal DNA (ecDNA), a significant driver of oncogenic gene amplification linked to treatment-resistant cancers. By utilizing artificial intelligence to identify and characterize ecDNA, the company aims to create targeted therapies that improve clinical outcomes for cancer patients.

ENPICOM provides a unified bioinformatics platform that integrates scalable data management, machine learning frameworks, and user-friendly analysis tools for lab and data scientists. This solution streamlines biologics discovery and engineering processes, enabling rapid data retrieval and model deployment while reducing reliance on specialized data science support.

Orbion provides an AI platform for comprehensive protein characterization, rational engineering, and automated experimental protocol generation. The platform integrates structure and omics data to predict PTMs, binding sites, and functional domains, accelerating discovery for diverse proteins and complexes. Researchers utilize Orbion to design optimized mutants and generate literature-validated bench protocols, significantly reducing wet-lab iteration time and cost.

Deep LS GmbH offers computational solutions to accelerate drug discovery and development for pharmaceutical and biopharmaceutical companies. Their platform utilizes machine learning to identify potential drug molecules, optimize their properties like solubility and ADME, and pinpoint binding sites on targets.

March Therapeutics utilizes proprietary molecular recording technologies and advanced computing to map protein sequences to their functions, enabling high-throughput exploration of enzymatic landscapes. This approach addresses the challenge of efficiently harnessing nature's biomolecular machines for the development of targeted genetic therapies.

Oxford Drug Design offers an AI‑powered platform that combines deep aaRS biology with proprietary algorithms such as EShape™ and SynthAI™ to perform ligand‑ and structure‑based virtual screening of a 6 M purchasable compound library. The workflow generates synthetically tractable candidates, ranks them with interpretable ML models via AIScape™, and delivers hit‑to‑lead optimization for pharmaceutical, biotech, and academic programs targeting oncology, infectious disease, and other high‑need areas.